BioPharma Dive March 27, 2024
Delilah Alvarado

An arm of the private equity firm has committed up to $750 million to support development Moderna’s mRNA-based vaccines for influenza.

Dive Brief:

  • Blackstone Life Sciences will invest as much as $750 million on influenza vaccine research and development by Moderna, announcing Wednesday a private funding deal that gives the private equity firm rights to future payments and royalties.
  • Moderna has advanced an mRNA-based flu shot into late-stage testing and is also studying a combination flu and COVID-19 vaccine — part of a broad R&D strategy to follow the success of its standalone COVID shot. Later this year, the company intends to submit the flu shot for regulatory approval.
  • The funding agreement comes one day after Moderna revealed results...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Related Articles:
11 drugs now in shortage
AbbVie tries to reassure investors on Humira biosimilar threat
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
This Biotech Startup Aims To Speed Up Drug Testing On Animals
Scientists reveal new method that could reduce waste from drug manufacturing

Share This Article